Impact of hepatitis C therapy on urinary outcomes and renal function: a prospective real-world cohort study of early kidney changes. [PDF]
Kaartinen K +4 more
europepmc +1 more source
Association between LDL-R (exon 8 C.1171 G > A) polymorphisms and response to antiviral therapy in hepatitis C virus infection. [PDF]
Shikhoun MEH, Ibrahim HAM, Abeed AAO.
europepmc +1 more source
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort. [PDF]
Suda G +25 more
europepmc +1 more source
Viral hepatitis after liver transplantation: A brief overview. [PDF]
Praharaj DL +8 more
europepmc +1 more source
DAAs in pregnancy are the only potential intervention to decrease vertical transmission: Pregnancy DAA data support safety. [PDF]
Chappell C, Biondi MJ, Kushner T.
europepmc +1 more source
A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. [PDF]
Jafari M +6 more
europepmc +1 more source
2025 KASL clinical practice guidelines for management of hepatitis C. [PDF]
Jang ES +11 more
europepmc +1 more source
[Recent Advances in the Treatment of Chronic Hepatitis C]. [PDF]
Kim SB.
europepmc +1 more source
Necrolytic acral erythema in an incarcerated population: A case series. [PDF]
Ali I, Cavanagh M, Kelly BC.
europepmc +1 more source
Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]
Luong CL +4 more
europepmc +1 more source

